Enanta Pharma (ENTA) Tops Q3 EPS by 39c, beats revenue

Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($1.86), $0.39 better than the analyst estimate of ($2.25). Revenue for the quarter came in at $18.89 million versus the consensus estimate of $18.19 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• General Mills (GIS) PT Lowered to $42 at Freedom Broker
• Pembina joins proposed 1M bbl/day Alberta-to-coast pipeline plan